Trials / Completed
CompletedNCT02015520
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to identify an appropriate dose of study medication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clazakizumab | |
| DRUG | Placebo (Matching with Clazakizumab) |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2013-06-01
- Completion
- 2015-06-01
- First posted
- 2013-12-19
- Last updated
- 2021-05-12
- Results posted
- 2021-04-19
Locations
55 sites across 9 countries: United States, Argentina, Canada, France, Hungary, Italy, Japan, Mexico, South Africa
Source: ClinicalTrials.gov record NCT02015520. Inclusion in this directory is not an endorsement.